These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23280499)

  • 1. Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
    Liu L; Unadkat JD
    Biopharm Drug Dispos; 2013 Apr; 34(3):155-64. PubMed ID: 23280499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
    Kirby BJ; Collier AC; Kharasch ED; Whittington D; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2011 Jun; 39(6):1070-8. PubMed ID: 21406602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
    Ye ZW; Camus S; Augustijns P; Annaert P
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes.
    Griffin LM; Watkins PB; Perry CH; St Claire RL; Brouwer KL
    Drug Metab Dispos; 2013 Jan; 41(1):188-96. PubMed ID: 23091188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.
    Liu L; Mugundu GM; Kirby BJ; Samineni D; Desai PB; Unadkat JD
    Biopharm Drug Dispos; 2012 May; 33(4):207-17. PubMed ID: 22498895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
    Chai H; Yang H; Yan S; Li M; Lin PH; Lumsden AB; Yao Q; Chen C
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):12-9. PubMed ID: 16123675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
    Jain RG; Lenhard JM
    J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
    Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
    Dixit V; Hariparsad N; Li F; Desai P; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2007 Oct; 35(10):1853-9. PubMed ID: 17639026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.
    Loutfy M; Raboud J; Thompson C; Tseng A; Abdurrahman Z; Kovacs C; Rachlis A; Phillips E; Rubin G; Gough K; Walmsley S
    HIV Clin Trials; 2003; 4(5):301-10. PubMed ID: 14583846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.
    Ye ZW; Van Pelt J; Camus S; Snoeys J; Augustijns P; Annaert P
    J Pharm Sci; 2010 Jun; 99(6):2886-98. PubMed ID: 20014428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
    Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
    Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.
    Kirby BJ; Collier AC; Kharasch ED; Dixit V; Desai P; Whittington D; Thummel KE; Unadkat JD
    Drug Metab Dispos; 2011 Dec; 39(12):2329-37. PubMed ID: 21930825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.